The notices it replaced
- Reissues: PAR-16-405 Single-Site Investigator-Initiated Clinical Trials (R61/R33)
Replaced by PAR-19-328.
Who won it before
21 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $16,957,381 in first-year total cost, median $750,258.
Most frequent study sections
- Special Emphasis Panel[ZHL1 CSR-G (M1)]10
- NHLBI Single-Site and Pilot Clinical Trials Study Section[SSPT (JA)]3
- Special Emphasis Panel[ZHL1 CSR-G (F1)]3
- Special Emphasis Panel[ZHL1 CSR-G (O2)]3
- NHLBI Single-Site and Pilot Clinical Trials Study Section[SSPT (OA)]1
Most frequent institutions
- OREGON HEALTH & SCIENCE UNIVERSITY2
- STANFORD UNIVERSITY2
- UNIVERSITY OF CALIFORNIA, SAN FRANCISCO2
- ALBERT EINSTEIN COLLEGE OF MEDICINE1
- EMORY UNIVERSITY1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2020 | Physical Activity to Improve CV Health in Older Women: A Pragmatic Trial1R61HL151885-01 | KOOPERBERG, CHARLES LLACROIX, ANDREA Z.STEFANICK, MARCIA L. | FRED HUTCHINSON CANCER RESEARCH CENTER, WA | $2,463,010 | SSPT |
| 2020 | Evaluation of the Asthma Management Program to Promote Activity for Students in Schools (Asthma-PASS)1R61HL147908-01A1 | REZNIK, MARINA | ALBERT EINSTEIN COLLEGE OF MEDICINE, NY | $867,721 | SSPT |
| 2020 | Maximizing Efficacy of Goal-Directed Sedation to Reduce Neurological Dysfunction in Mechanically Ventilated Infants and Children Study (mini-MENDS)1R61HL151951-01 | PANDHARIPANDE, PRATIKSMITH, HEIDI A B | VANDERBILT UNIVERSITY MEDICAL CENTER, TN | $855,283 | SSPT |
| 2020 | RE-ENERGIZE FONTAN - RandomizEd Exercise INtERvention desiGned to MaximIZE Fitness in Pediatric FONTAN patients1R61HL146775-01A1 | BERNSTEIN, DANIELPALANIAPPAN, LATHA PSELAMET TIERNEY, ELIF SEDA | STANFORD UNIVERSITY, CA | $752,734 | SSPT |
| 2019 | Point-of-care C-reactive protein-based tuberculosis screening in people living with HIV: a randomized trial1R61HL146365-01A1 | DOWDY, DAVID WESLEYPHILLIPS, PATRICK PJYOON, CHRISTINA | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA | $963,941 | ZHL1 |
| 2019 | Guys/Girls Opt for Activities for Life (GOAL) Trial1R61HL144896-01A1 | ROBBINS, LORRAINE BRENDA | MICHIGAN STATE UNIVERSITY, MI | $788,377 | ZHL1 |
| 2019 | A Mobile Relational Agent to Enhance Atrial Fibrillation Self-care1R61HL144669-01 | MAGNANI, JARED W. | UNIVERSITY OF PITTSBURGH AT PITTSBURGH, PA | $766,398 | ZHL1 |
| 2019 | Randomized Explanatory Trial of a Mediterranean Dietary Pattern Weight Loss Intervention for Primary Care Practices1R61HL142680-01A1 | KEYSERLING, THOMAS CSAMUEL-HODGE, CARMEN D | UNIV OF NORTH CAROLINA CHAPEL HILL, NC | $759,424 | ZHL1 |
| 2019 | A Pharmacist Intervention for Monitoring and Treating Hypertension Using Bidirectional Texting1R61HL144880-01A1 | CARTER, BARRY LPOLGREEN, LINNEA ANN | UNIVERSITY OF IOWA, IA | $693,432 | ZHL1 |
| 2019 | Extending CPAP Therapy in Stable Preterm Infants to Increase Lung Growth and Function: A Randomized Controlled Trial1R61HL147906-01 | MCEVOY, CYNTHIA TTEPPER, ROBERT S. | OREGON HEALTH & SCIENCE UNIVERSITY, OR | $657,183 | ZHL1 |
| 2019 | PCSK9 Inhibition after Heart Transplantation1R61HL139929-01A1 · under PAR-16-405 | FEARON, WILLIAM F | STANFORD UNIVERSITY, CA | $435,534 | ZHL1 |
| 2018 | A double-blind randomized controlled trial to assess the efficacy and safety of a quadruple ultra-low-dose treatment for hypertension (QUARTET USA)1R61HL139852-01 · under PAR-16-405 | CIOLINO, JODY D.HUFFMAN, MARK D | NORTHWESTERN UNIVERSITY AT CHICAGO, IL | $1,228,452 | ZHL1 |
| 2018 | Advanced REperfusion STrategies- The ARREST Trial1R61HL142696-01 · under PAR-16-405 | AUFDERHEIDE, TOM PAULYANNOPOULOS, DEMETRIS | UNIVERSITY OF MINNESOTA, MN | $750,258 | ZHL1 |
| 2018 | Effect of PCSK9 Inhibition on Cardiovascular Risk in Treated HIV Infection (EPIC-HIV Study)1R61HL141047-01 · under PAR-16-405 | HOFFMANN, UDOHSUE, PRISCILLA Y.TAWAKOL, AHMED A | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA | $729,903 | ZHL1 |
| 2018 | REHAB-PH Trial: Repurposing a Histamine Antagonist to Benefit Patients with Pulmonary Hypertension1R61HL142539-01 · under PAR-16-405 | LEARY, PETER J | UNIVERSITY OF WASHINGTON, WA | $685,472 | ZHL1 |
| 2018 | Randomized Trial of Endotracheal Tubes to Prevent Ventilator-Associated Pneumonia - Prevent 2 Study1R61HL138650-01A1 · under PAR-16-405 | AZIZ, MICHAELTREGGIARI, MIRIAM | OREGON HEALTH & SCIENCE UNIVERSITY, OR | $657,073 | ZHL1 |
| 2018 | Comparative effectiveness of social physical play and traditional exercise programming1R61HL142679-01 · under PAR-16-405 | SCIAMANNA, CHRISTOPHER N. | PENNSYLVANIA STATE UNIV HERSHEY MED CTR, PA | $643,916 | ZHL1 |
| 2018 | The Effects of Interleukin-1 Blockade On Exercise Capacity In Patients With Recently Decompensated Systolic Heart Failure1R61HL139943-01 · under PAR-16-405 | ABBATE, ANTONIOVAN TASSELL, BENJAMIN W | VIRGINIA COMMONWEALTH UNIVERSITY, VA | $532,674 | ZHL1 |
| 2018 | Targeting of UnControlled Hypertension in Emergency Department (TOUCHED)1R61HL139454-01A1 · under PAR-16-405 | PRENDERGAST, HEATHER MARIE | UNIVERSITY OF ILLINOIS AT CHICAGO, IL | $505,284 | ZHL1 |
| 2018 | Behavioral Economic Approaches to Increase Physical Activity among Patients with Elevated Risk for Cardiovascular Disease1R61HL141440-01 · under PAR-16-405 | PATEL, MITESH S.VOLPP, KEVIN G | UNIVERSITY OF PENNSYLVANIA, PA | $446,212 | ZHL1 |
| 2017 | Granulocyte-Macrophage Colony Stimulated Factor (GM-CSF) in Peripheral Arterial Disease1R61HL138657-01 · under PAR-16-405 | QUYYUMI, ARSHED A | EMORY UNIVERSITY, GA | $775,100 | ZHL1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.